Discovery finds path for Surfaxin approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
After meeting with FDA on Sept. 29, Discovery Labs has agreed with the agency on an approach to resolving the remaining primary issue standing in the way of approval of its Surfaxin (lucinactant), a surfactant for prevention of Respiratory Distress Syndrome in premature infants. Discovery received a "complete response" letter on the application April 17; it was the fourth action letter on the application (1Pharmaceutical Approvals Monthly April 2009). The firm has identified a new program for optimization and final method validation of its fetal rabbit Biological Activity Test (a quality control and stability release test that can distinguish change in Surfaxin biological activity over time) and a proposed "limited Surfaxin clinical trial design," which would employ the new BAT. The additional trial would primarily assess pharmacodynamic response following Surfaxin administration in preterm infants, the company explained. The final design will be submitted to FDA for review mid-fourth quarter 2009
You may also be interested in...
Discovery escapes clinical trial requirement for Surfaxin
Discovery Labs no longer has to conduct an additional clinical trial for its respiratory distress syndrome agent Surfaxin (lucinactant), following written guidance recently received from FDA, the firm announced Feb. 16. The agency has determined that all that is needed is additional preclinical work for Surfaxin, which has been through four review periods already, to gain approval to prevent RDS in premature infants. Discovery had previously disclosed an agreement with FDA that an additional, limited clinical trial would be done for final validation of a fetal rabbit biological activity test (a quality control adjustment to address a lingering chemistry, manufacturing and controls issue) (1Pharmaceutical Approvals Monthly, October 2009). However, because an acceptable model of RDS exists - preterm lambs - the model can be used for the BAT validation instead. The new option "presents an opportunity to significantly reduce the time and expense needed to gain approval," and the firm plans to submit a full response in the first quarter of 2011
Will fourth action letter be the charm for Discovery’s Surfaxin?
The fourth review cycle for its Surfaxin (lucinactant) NDA with a fourth action letter, Discovery Labs announces April 20. FDA's primary issue in the latest complete response letter centers on whether a biological activity test used for quality control, stability and release testing "can adequately distinguish change of Surfaxin drug product over time," CEO Robert Capetola told an April 20 teleconference to discuss the NDA for the synthetic surfactant for prevention of respiratory distress syndrome in premature infants. "The data to address these issues with FDA on this BAT already reside with the FDA," Capetola said. The company's response to the third action letter included preclinical studies related to the BAT, Discovery noted last autumn (1Pharmaceutical Approvals Monthly October 2008, In Brief). "We're going to request an end-of-review meeting with the FDA to take place as soon as possible," Capetola said. He noted that the necessary data, "submitted through multiple NDA filings over the years," could be "somewhat fragmented." The CEO stressed that the company must "represent the existing information in front of FDA in a way that clearly defines the capabilities of the BAT as we described it and documented it for them.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.